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Previewsto Neanderthals. A group of PD-1 alleles
that are strongly selected for and main-
tained at a high frequency of homozy-
gosity in Asian populations is similar to
Neanderthal but not Denisovan genomes.
This is most consistent with the idea that
interbreeding led to introduction of these
human alleles into the Neanderthal
genome and with selection due to
shared local pressures, such as com-
mon pathogens, in human and Nean-
derthal populations in Asia. It appears
that a little humanity was good for the
Neanderthal.
Forni et al. found that for seven of
13 disease-associated SNPs in genes
encoding T cell regulatory molecules, the
frequency of the risk allele increased
with the diversity of at least one pathogen
group. Six of these seven disease-associ-
ated SNPs were autoimmune-disease-
associated variants that correlated
positively with pathogen diversity. This is
consistent with autoimmune-disease risk
alleles’ conferring protection against
pathogens and selection of these alleles
as adaptation to pathogen-driven selec-
tive pressures. The one disease-associ-
ated SNP in which the risk allele was
negatively associated with pathogen
load was a FAS variant associated with
IgA deficiency. This negative correlation
would be expected as a result of the
increased risk of life-threatening infec-
tions in individuals with IgA deficiency.
Genome-wide association studies
(GWASs) have identified several hundredloci associated with various diseases.
When GWASs first identified noncoding
SNPs as associated with disease, most
biologists expected that these were con-
venient followers of some coding variant
that was the true disease-associated
change. This has turned out rarely to be
the case, and identifying the causal muta-
tion in a locus has been difficult. The
coding variation in humans is surprisingly
limited, and only an estimated 0.5% of
nonsynonymous amino acid changes in
the past 250,000 years have been posi-
tively selected. This suggests a startlingly
low number of nonsynonymous adaptive
mutations in the human genome; that
number is estimated to be less than 340
(Grossman et al., 2013; Hernandez et al.,
2011). Grossman et al. estimated only 38
causal nonsynonymous amino acid
changes among 412 GWAS-selected
loci (Grossman et al., 2013). These results
and those of Forni et al. suggest that the
great majority of selected mutations
occur in regulatory elements that control
gene expression, rather than in coding re-
gions (Grossman et al., 2013; Hernandez
et al., 2011; Jostins et al., 2012). Forni
et al. demonstrate that allelic variation in
the T cell regulatory genes is associated
with selective pressures from pathogens,
and this pressure for the immune
response to be faster or stronger has
selected for autoimmune-disease-asso-
ciated alleles in these genes. Thus, immu-
nity can be a choice between a rock and a
hard place.Immunity 3REFERENCES
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Unwarranted NLRP3 activation causes inflammatory disease. Its activation must therefore be specifically
licensed. In this issue of Immunity, Munoz-Planillo et al. (2013) reveal K+ efflux as the sole common denom-
inator of an array of unrelated stimuli engaging this inflammasome.The NLRP3 inflammasome was originally
identified through its association with
three hereditary autoinflammatory syn-dromes that are characterized by urticar-
ial skin rashes and prolonged episodes
of fever. An important subset of patientssuffering from the autosomal-dominant
periodic fever syndromes—familial cold
autoinflammatory syndrome (FCAS),8, June 27, 2013 ª2013 Elsevier Inc. 1085
Figure 1. Model for NLRP3 Inflammasome Activation
Assembly and activation of the NLRP3 inflammasome is a stringently regulated process that requires
signaling from pattern recognition or cytokine receptors to induce NF-kB-mediated upregulation of
Nlrp3 and pro-IL-1b transcripts (step 1). Deubiquitination of NLRP3 by BRCC3 (step 2) is a prerequisite
for its activation. A stimulus-induced decrease in intracellular K+ concentrations consequent to K+ efflux
through purinergic receptors, pore-forming toxins, ionophores, or larger membrane pores lowers the
threshold for NLRP3 activation (step 3). Soluble, particulate, and crystalline NLRP3 stimuli further generate
an unknown secondary messenger that triggers assembly of the NLRP3 inflammasome (step 4), which
then matures and allows secretion of its substrate pro-IL-1b (step 5).
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PreviewsMuckle-Wells syndrome (MWS), and
chronic infantile neurological cutaneous
and articular syndrome (CINCA)—turned
out to harbor gain-of-function mutations
in and around the central NACHT domain
of NLRP3 (Lamkanfi and Dixit, 2012).
These mutations are believed to force
NLRP3 in a conformational state that
removes the necessity for a molecular
agonist to drive its activation, resulting in
spontaneous assembly of the inflamma-
some, activation of the cysteine protease
caspase-1, and secretion of the inflam-
masome substrates interleukin-1b (IL-1b)
and IL-18. Subsequent reports—to a
significant extent based on the analysis
of Nlrp3-deficient mice—further estab-
lished a causal relationship between
unwarranted NLRP3 signaling and the
ethiology of Crohn’s disease, colitis,
atherosclerosis, contact hypersensitivity,
metabolic syndrome, and Alzheimer’s
disease; whereas other studies revealed
its critical role in host defense against a
diverse set of bacterial, viral, and fungal
pathogens (Lamkanfi and Dixit, 2012).
In cultured macrophages and dendritic
cells, the NLRP3 inflammasome re-1086 Immunity 38, June 27, 2013 ª2013 Elsesponds to endogenous danger-associ-
ated molecular patterns (DAMPs) such
as ATP and hyaluronan. In addition,
monosodium urate (MSU) crystals, amy-
loid-b fibrils and exogenous crystalline
particles including alum, silica, asbestos,
and nanomaterials all stimulate NLRP3
activation. Immune cells also respond
to the action of pore-forming toxins
such as maitotoxin, a-hemolysin, grami-
cidin, and the ionophore nigericin with
NLRP3 inflammasome activation. Given
its broad impact on diverse homeostatic
systems, Nlrp3 inflammasome activation
is stringently controlled (Figure 1). Basal
Nlrp3 expression levels in naive macro-
phages and dendritic cells are low, and
NF-kB-driven upregulation of Nlrp3
expression is the first hurdle to be taken
to ready the NLRP3 inflammasome for
activation (Lamkanfi and Dixit, 2012).
Recent reports refer to a second post-
transcriptional checkpoint at which
deubiquitination licenses NLRP3 for
activation (Juliana et al., 2012; Py et al.,
2013). However, Nlrp3 inflammasome
activation in TLR-activated cells only
will occur upon exposure to a secondvier Inc.stimulus from the list above comprising
ATP, nigericin, and silica.
Given the wide array of pathophy-
siological conditions and chemically
unrelated stimuli activating the NLRP3
inflammasome, it is commonly thought
that NLRP3 does not physically interact
with these molecular entities directly but
rather guards a host-derived secondary
messenger, the homeostatic concentra-
tion of which is commonly perturbed by
NLRP3-activating stimuli. Multiple such
secondary messengers have been put
forward in recent years, including K+
efflux, lysosomal destabilization, mem-
brane permeabilization, mitochondrial
damage, and release of oxidized DNA,
the production of reactive oxygen species
(ROS), Ca2+ influx, and cell swelling
(Lamkanfi and Dixit, 2012). Although
each of these mechanisms was proposed
based on the analysis of the cellular
responses elicited by a number of the
NLRP3-activating stimuli above, most
models have not been evaluated for
larger sets of the ever-growing list of
NLRP3-activating molecules. Based on a
more comprehensive analysis of the
cellular events triggered by an extended
panel of NLRP3 stimuli that belong
to distinct biochemical categories,
Munoz-Planillo et al., (2013) in this issue
of Immunity concluded most of the
proposed secondary messengers as
being dispensable for NLRP3 activation
because they were not shared by all
tested NLRP3-activating triggers.
In this regard, oxidative mitochondrial
damage and ROS production were
deemed not to be critical because
NLRP3 activation was not observed in
response to uncoupling of the mitochon-
drial respiratory chain with rotenone,
oligomycin and antimycin A, nor upon
inhibition of autophagy or exogenous
ROS generation with H2O2 (Munoz-
Planillo et al., 2013). Moreover, the
change in metabolic rate observed with
gramicidin, nigericin, and ATP temporally
lagged NLRP3 activation. In addition, the
authors show that the metabolic effect
of gramicidin, nigericin, and ATP was
rescued by the Na+-K+-ATPase inhibitor
ouabain without affecting their potency
to induce NLRP3 inflammasome activa-
tion, although interpretation of the latter
experiment is somewhat complicated by
the fact that ouabain autonomously in-
duces NLRP3-dependent IL-1b release
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Previews(Munoz-Planillo et al., 2013; Walev et al.,
1995). Finally, concentrations of ROS
scavengers that were sufficient to inhibit
the cellular redox state appeared inca-
pable of inhibiting NLRP3 inflammasome
activation. These results are supported
by recent observations suggesting that
higher concentrations of these ROS
scavengers might interfere with NF-kB-
mediated transcriptional priming rather
than posttranslational activation of the
NLRP3 inflammasome (Bauernfeind
et al., 2011).
Instead of the above models, Munoz-
Planillo et al. identified K+ efflux as the
sole common denominator induced by
all classes of tested NLRP3-activating
stimuli (Figure 1). Indeed, cellular K+
depletion by the H+-K+ ionophore nigeri-
cin, staphylococcal a-hemolysin, grami-
cidin, and the purinergic P2X7 receptor
has long been recognized and was previ-
ously linked to posttranslational matura-
tion and secretion of bioactive IL-1b
from LPS-primed macrophages (Walev
et al., 1995). The realization that these
molecules all induced IL-1b maturation
through the NLRP3 inflammasome set
the stage for demonstrating that NLRP3
activation by molecules without apparent
membrane-permeating properties—such
as crystalline MSU—also was inhibited
by high extracellular K+ concentrations
(Pe´trilli et al., 2007). Munoz-Planillo et al.
further established that phagosomal
uptake of crystalline and particulate
molecules such as silica, alum, and cal-
cium pyrophosphate dihydrate (CPPD)
crystals by LPS-primed macrophages
was accompanied by a significant drop
in the intracellular K+ concentration
that preceded NLRP3-dependent IL-1b
secretion. Notably, the phagocytosis
inhibitors cytochalasin B and latrunculin
B impaired both K+ efflux and NLRP3
inflammasome activation by crystalline
substances, suggesting that cellular
uptake is required for both events to
occur. In this regard, activation of
NLRP3 by media containing high extra-
cellular concentrations of Ca2+ and phos-
phate was attributed to the formation
of insoluble calcium phosphate salts
(Munoz-Planillo et al., 2013), which were
previously linked to K+ efflux and NLRP3
inflammasome activation (Jin et al.,
2011). Moreover, preventing lysosomal
and endosomal acidification with Bafilo-
mycin A blocked NLRP3 activationand K+ efflux by crystalline agents and
the lysosomotropic peptide derivative
LL-OMe, but not by nigericin and ATP
(Munoz-Planillo et al., 2013). This sug-
gests that endosomal acidification might
be specifically required for inducing a
drop in intracellular K+ concentration
and NLRP3 inflammasome activation by
crystalline and lysosomotropic, but not
soluble agents. In this regard, it is inter-
esting to note that Munoz-Planillo et al.
monitored K+ efflux indirectly by mea-
suring changes in the intracellular con-
centration of this cation. Although
drops in intracellular K+ levels usually
are caused by its extracellular release
through membrane-associated pores
and channels, it could also reflect its dilu-
tion by cellular volume changes resultant
from water influx driven by osmosis.
Notably, a recent report suggested a
model in which NLRP3 activation by in-
gested MSU crystals would result from
the release of high amounts of Na+ under
the acidic conditions found in maturing
endosomes and lysosomes. Cytosolic
release of crystal-derived Na+ from
damaged organelles in turn would trigger
an influx of water and an accompanying
cellular volume increase that drops the
intracellular K+ concentration below the
threshold licensing NLRP3 activation
(Schorn et al., 2011). In support of this
model, experimental removal of sodium
from the crystals prevented secretion of
IL-1b—but not IL-6—from macrophages
ingesting Na+-free crystals (Schorn et al.,
2011), although this treatment could as
well cause lattice changes in the crystal
that decreased its intrinsic capacity to
activate NLRP3. Although they did not
test MSU crystals, Munoz-Planillo et al.
showed that other crystalline NLRP3
stimuli permeabilized the membrane
for ethidium and taurine rather early,
suggesting that extracellular K+ efflux
accounts—at least partially—for the
observed decrease in intracellular K+
levels induced by MSU. In addition, they
showed that K+-free buffers decreased
intracellular K+ levels and triggered
NLRP3 inflammasome activation in the
absence of osmosis (Munoz-Planillo
et al., 2013), suggesting cell swelling
to at least be dispensable for NLRP3
activation by noncrystalline compounds.
The observation that unlike the
NLRP3 inflammasome, activation of the
AIM2 inflammasome by transfectedImmunity 3double-stranded DNA was not accom-
panied by a decrease in intracellular K+
concentrations firmly establishes a regu-
latory role for K+ in modulating NLRP3
activation thresholds at the level of
NLRP3 itself or upstream in the pathway.
In support of this conclusion, LPS-treat-
ment of macrophages expressing the
MWS-associated constitutively active
NLRP3R258W mutant triggered caspase-1
activation and IL-1b release in theabsence
of K+ efflux, and high K+ concentrations
failed to prevent these events (Munoz-
Planillo et al., 2013). This suggests that
elevated intracellular K+ concentrations
might hamper wild-type NLRP3 to un-
dergo the conformational changes that
are induced by the MWS-associated
mutation. Alternatively, K+ might inhibit a
factor upstream of NLRP3 that signals
such conformational changes.
Thus, collectively these results suggest
that K+ efflux might reduce the threshold
for NLRP3 activation. As such, the
NLRP3 inflammasome might resemble
the apoptosome in that both are cyto-
solic caspase-activating protein plat-
forms (caspase-1 versus caspase-9,
respectively), the assembly and activa-
tion of which is inhibited by physiological
K+ concentrations (Cain et al., 2001).
Once assembled, both complexes are
rather insensitive to ionic perturbations.
The role of K+ efflux in this model
entails the removal of a checkpoint
safeguarding the cell against unwar-
ranted complex assembly caused by
the inadvertent release of small amounts
of their respective ligands (unknown
versus cytochrome c, respectively).
However, because K+ efflux also has
been implicated in activation of the
NLRP1b inflammasome by anthrax lethal
toxin (Pe´trilli et al., 2007), further work
is needed to determine whether it repre-
sents the long-sought-after secondary
messenger that is specifically sensed
by the NLRP3 inflammasome.REFERENCES
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Activation of inflammasome signaling can produce harmful inflammation. In this issue of Immunity,
Yan et al. (2013) suggest that omega-3 fatty acids commonly found in marine oils can suppress activation
of NLRP3 and NLRP1b inflammasomes.Marine-derived omega-3 (u-3) polyunsat-
urated fatty acids (FA) such as
docosahexaenoic acid (DHA) and eico-
sapentaenoic acid (EPA) exhibit anti-
inflammatory properties (Oh et al., 2010),
but exact mechanisms for these proper-
ties are not fully understood. u-3 FAs
inhibit inflammatory cytokines such as
interleukin-1b (IL-1b) (Oh et al., 2010),
prompting interest in the idea that u-3
FAs can inhibit inflammasomes. In this
issue of Immunity, Yan et al. (2013)
provide insight into details of how such
an inhibition may occur.
Inflammasomes are intracellular pro-
tein complexes that serve as sensors
of microbial and endogenous cellular
insults (Davis et al., 2011; Vladimer et al.,
2013). Release of inflammasome-derived
IL-1b and IL-18 typically occurs in a
two-step process: triggering of a Toll-like
receptor (TLR) that primes the inflam-
matory response (‘‘signal 1’’) and intra-
cellular danger signals that initiate for-
mation of the inflammasome complex
(‘‘signal 2’’).
The NLRP3 inflammasome is acti-
vated by a large and diverse array of
pathogens, as well as endogenous and
exogenous sterile agonists and danger
signals. It is not surprising that NLRP3has been implicated to play a role in
several inflammatory disorders such as
gout and atherosclerotic disease by
potentially sensing uric acid crystals
and cholesterol crystals, respectively
(Davis et al., 2011; Duewell et al.,
2010). Recent evidence pointed to a
role for inflammasomes in initiating
obesity-induced inflammation and insu-
lin resistance related to type 2 diabetes
(Vandanmagsar et al., 2011; Henao-
Mejia et al., 2012) and other metabolic
disorders (Davis et al., 2011). The in-
crease in obesity and chronic inflam-
matory states underscores the need for
clinical therapeutics to prevent and treat
inflammation.
Because u-3 FAs can inhibit proin-
flammatory cytokines such as tumor
necrosis factor (TNF) and IL-1b (Oh
et al., 2010) and NLRP3 activation pro-
motes IL-1 b release, Yan et al. (2013)
set out to examine the possibility that
thwarting IL-1b release by u-3 FAs was
mediated by blocking inflammasome
activation. They confirmed that pretreat-
ing cells with DHA prior to stimulation
blocked caspase-1 activation and IL-1b
and IL-18 production. The u-3 FA EPA
and to a lesser extent the plant-derived
a-Linolenic acid (ALA) also blockedIL-1b, but u-6 and u-9 FAs had no
effect, indicating this inhibition is specific
for certain u-3 FAs.
DHA inhibited activation for all NLRP3
agonists tested, but failed to inhibit
activation induced by triggers of other
inflammasome components, such as
Salmonella (NLRC4 inflammasomes) or
DNA (AIM2 inflammasomes). However,
DHA also blocked activation of the
NLRP1b inflammasome, which is stimu-
lated by the microbial anthrax lethal
toxin. This finding suggested u-3 FAs
as specific inhibitors of NLRP3 and
NLRP1b inflammasomes.
The surface-exposed G protein-
coupled receptor 120 (GPR120) can
mediate anti-inflammatory effects of
DHA and EPA (Oh et al., 2010). By inhibit-
ing or decreasing expression of both
GPR120 and GPR40, DHA treatment no
longer repressed caspase-1 activation
and IL-1b release compared to partial
restoration of cytokine release when
GPR120 or GPR40 were individually in-
hibited. Therefore, u-3 FAs signal through
GPR120 and GPR40 to inhibit NLRP3
activation.
Additional mechanistic investigations
revealed that gene targeting of the
GPR120 downstream scaffold protein
